カテゴリ： GlobalData, アメリカ, 企業調査

Vertex Pharmaceuticals Inc (VRTX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014219
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：82
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of novel drugs for the treatment of serious and life-threatening diseases. The company offers Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Its research and development efforts focus on influenza and bacterial infections, inflammatory diseases, cancer, neurological diseases and disorders including pain and cystic fibrosis. The company has several pipeline products for the treatment of cystic fibrosis, cancer, pain and influenza. It has operations in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc (VRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Partnerships 16
X-Chem Enters into Agreement with Vertex Pharma 16
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 17
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 18
Vertex Pharma Extends Co-Development Agreement With Cystic Fibrosis Foundation 19
Licensing Agreements 21
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Asset Transactions 27
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc – Key Competitors 30
Vertex Pharmaceuticals Inc – Key Employees 31
Vertex Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 35
Financial Announcements 35
Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 35
Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 38
Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 41
Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 44
Oct 25, 2016: Vertex Reports Third Quarter 2016 Financial Results 46
Jul 27, 2016: Vertex Reports Second Quarter 2016 Financial Results 48
Apr 27, 2016: Vertex Reports First Quarter 2016 Financial Results 50
Jan 27, 2016: Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results 54
Corporate Communications 57
Oct 17, 2017: Vertex Announces 10-Year, $500 Million Corporate Giving Commitment 57
Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 58
Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 59
Dec 02, 2016: Vertex Pharmaceuticals Announces Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 60
Government and Public Interest 61
Nov 01, 2017: Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 61
May 04, 2017: Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 62
Feb 24, 2016: Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 63
Product Approvals 64
Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 64
Clinical Trials 65
Nov 03, 2017: Vertex Announces Presentation of Data from Triple Combination (VX-440, VX-152 and VX-659) Regimen Studies at North American Cystic Fibrosis Conference 65
Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 66
Dec 21, 2016: Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis 67
Oct 27, 2016: Concert Pharmaceuticals Presents Poster at 2016 North American Cystic Fibrosis Conference 68
Oct 25, 2016: Vertex Announces Planned Initiation of Phase 2 Study Evaluating the Next-Generation Corrector VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis 69
Oct 25, 2016: Vertex Announces Planned Initiation of Phase 2 Study Evaluating the Next-Generation Corrector VX-440 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis 70
Oct 25, 2016: Vertex to Begin Clinical Development of Third Next-Generation Corrector VX-659 71
Jun 10, 2016: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference 72
Apr 28, 2016: Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis 73
Feb 29, 2016: Concert Pharmaceuticals Announces CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile to Kalydeco 74
Other Significant Developments 75
Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 75
Jan 10, 2016: Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases 78
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
X-Chem Enters into Agreement with Vertex Pharma 16
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 17
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 18
Vertex Pharma Extends Co-Development Agreement With Cystic Fibrosis Foundation 19
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc, Key Competitors 30
Vertex Pharmaceuticals Inc, Key Employees 31
Vertex Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[Vertex Pharmaceuticals Inc (VRTX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Tieto Corp (TIETO)：企業の財務・戦略的SWOT分析
    Tieto Corp (TIETO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Cochlear Ltd (COH)：企業の製品パイプライン分析
    Summary Cochlear Ltd (Cochlear) is a medical device company that offers implantable hearing solutions. It develops, manufactures and markets electronic implantable hearing devices. The company’s products are suited for people with hearing loss caused by ear nerve damage. Its major products include c …
  • Cochin Shipyard Ltd (COCHINSHIP)：企業の財務・戦略的SWOT分析
    Cochin Shipyard Ltd (COCHINSHIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Phibro Animal Health Corp (PAHC)：企業の財務・戦略的SWOT分析
    Phibro Animal Health Corp (PAHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sempra Energy：企業の戦略・SWOT・財務情報
    Sempra Energy - Strategy, SWOT and Corporate Finance Report Summary Sempra Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lundin Gold Inc：戦略・SWOT・企業財務分析
    Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report Summary Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • meteocontrol GmbH：電力：M&Aディール及び事業提携情報
    Summary Meteocontrol GmbH (meteocontrol) a subsidiary of S.A.G. Solar GmbH & Co. KG, is a renewable energy company which offers photovoltaic monitoring solutions. The company's product portfolio includes data loggers, WEB'logs, portals, sensor system, grid feed-in management or power control, SCADA …
  • NiSource Inc (NI)：石油・ガス：M&Aディール及び事業提携情報
    Summary NiSource Inc (NiSource) is a regulated energy utility. The company distributes natural gas; and generates, transmits and distributes electricity. It produces electricity from coal, gas and hydro sources. NiSource operates electricity transmission systems and natural gas transmission pipeline …
  • Bajaj Finance Ltd (BAJFINANCE)：企業の財務・戦略的SWOT分析
    Bajaj Finance Ltd (BAJFINANCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Abide Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Abide Therapeutics Inc (Abide) is a clinical development stage company that discovers and develops therapeutic potential of serine hydrolases to transform the lives of patients with serious unmet medical needs. The company’s pipeline include ABX-1431, a first-in-class inhibitor of the serine …
  • Sioux Manufacturing Corporation：企業の戦略・SWOT・財務情報
    Sioux Manufacturing Corporation - Strategy, SWOT and Corporate Finance Report Summary Sioux Manufacturing Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • DEME NV：企業の戦略的SWOT分析
    DEME NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Claire’s Stores Inc：企業の戦略・SWOT・財務分析
    Claire's Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Claire's Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Saudi Industrial Export Company (4140)：企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Export Company (SIEC) is a chemical providing company that imports, exports and sales specialty chemicals, fertilizers, industrial materials and commodities. The company's fertilizers include diammonium phosphate, sulphur, urea, triple super phosphate, granular triple super …
  • Gr. Sarantis S.A. (SAR)：企業の財務・戦略的SWOT分析
    Gr. Sarantis S.A. (SAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Electricity Generating Public Co Ltd (EGCO)：電力：M&Aディール及び事業提携情報
    Summary Electricity Generating Public Co Ltd (EGCO), a subsidiary of Electricity Generating Authority of Thailand (EGAT), is an energy utility. It produces electricity from natural gas, coal, biomass, waste, hydro, solar, wind, and geothermal sources. Through interests in independent power producer …
  • Shanghai Kehua Bio-engineering Co Ltd (002022)：企業の財務・戦略的SWOT分析
    Shanghai Kehua Bio-engineering Co Ltd (002022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Lockton, Inc：企業の戦略・SWOT・財務情報
    Lockton, Inc - Strategy, SWOT and Corporate Finance Report Summary Lockton, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • China Animal Husbandry Industry Co Ltd (600195)：企業の財務・戦略的SWOT分析
    China Animal Husbandry Industry Co Ltd (600195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Epigenomics AG (ECX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆